Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Curogen Technology
Seoul, South Korea
- Ownership
- Private
- Employees
- ~50
- Development stage
- Other
01
Overview
Curogen Technology is a preclinical-stage biotechnology company focused on autoimmune diseases. It is currently advancing two lead assets toward IND submission by late 2026: an oral small molecule for inflammatory bowel disease and a multispecific biologic for hidradenitis suppurativa.
- Therapeutic areas
- ImmunologyNeurologyDermatologyGastroenterology
- Modalities
- Small moleculeRecombinant fusion proteinMultispecific proteinProtein
- Industry
- Biotech
02
Partnerships
Korea Drug Development Fund (KDDF)
Beyond the preview
Go deeper on Curogen Technology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Curogen Technology.